BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/13/2021 12:57:54 PM | Browse: 586 | Download: 1004
 |
Received |
|
2021-03-01 11:43 |
|
Peer-Review Started |
|
2021-03-01 11:50 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-06-16 02:11 |
|
Revised |
|
2021-06-30 04:17 |
|
Second Decision |
|
2021-08-03 03:29 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-08-03 09:23 |
|
Articles in Press |
|
2021-08-03 09:23 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-08-16 09:48 |
|
Typeset the Manuscript |
|
2021-10-08 02:07 |
|
Publish the Manuscript Online |
|
2021-10-13 12:57 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Thermal ablation and immunotherapy for hepatocellular carcinoma: Recent advances and future directions
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Xiao-Wan Bo, Li-Ping Sun, Song-Yuan Yu and Hui-Xiong Xu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
81801802 |
| National Natural Science Foundation of China |
81725008 |
| Shanghai Municipal Health Commission |
2019LJ21 |
| Shanghai Municipal Health Commission |
SHSLCZDZK03502 |
| Science and Technology Commission of Shanghai Municipality |
19DZ2251100 |
| Science and Technology Commission of Shanghai Municipality |
19441903200 |
| Science and Technology Commission of Shanghai Municipality |
18441905500 |
| Shanghai “Rising Stars of Medical Talent” Youth Development Program |
|
|
| Corresponding Author |
Hui-Xiong Xu, PhD, Doctor, Doctor, Department of Medical Ultrasound, Shanghai Tenth People’s Hospital; Ultrasound Research and Education Institute, Clinical Research Center for Interventional Medicine, Cancer Center, Tongji University School of Medicine; Shanghai Engineering Research Center of Ultrasound Diagnosis and Treatment; National Clinical Research Center for Interventional Medicine, No. 301 Yanchangzhong Road, Shanghai 200072, China. xuhuixiong@126.com |
| Key Words |
Hepatocellular carcinoma; Thermal ablation; Radiofrequency ablation; Immunotherapy; Recurrence; Anti-tumor immune response |
| Core Tip |
Hepatocellular carcinoma (HCC) is one of the most leading causes of death in the world. Thermal ablation (TA) is an important treatment method for HCC patients. The main disadvantage of TA for HCC is the high local and distant recurrence rates after treatment. Immunotherapy is a novel systemic treatment that presents potential efficacy to inhibit the tumor recurrence. The combination of local TA and immunotherapy for HCC may be an ideal treatment for enhancing the efficacy of TA and controlling the recurrence. We herein summarize the latest progress in TA, immunotherapy, and the combination of TA with immunotherapy for HCC and discuss the future directions of the combined therapy. |
| Publish Date |
2021-10-13 12:57 |
| Citation |
Bo XW, Sun LP, Yu SY, Xu HX. Thermal ablation and immunotherapy for hepatocellular carcinoma: Recent advances and future directions. World J Gastrointest Oncol 2021; 13(10): 1397-1411 |
| URL |
https://www.wjgnet.com/1948-5204/full/v13/i10/1397.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v13.i10.1397 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
